(MedPage Today) — PHILADELPHIA — Peanut allergy immunotherapy delivered by an investigational skin patch increased the proportion of children ages 4 to 7 years who could tolerate a dose of peanut protein in the phase III VITESSE trial.
After…
Source link : https://www.medpagetoday.com/meetingcoverage/aaaai/120108
Author :
Publish date : 2026-03-02 15:51:00
Copyright for syndicated content belongs to the linked Source.
